Commure vs CoverMyMeds

Side-by-side comparison of AI visibility scores, market position, and capabilities

CoverMyMeds leads in AI visibility (90 vs 34)
Commure logo

Commure

EmergingHealthcare

Healthcare Infrastructure

$200M funding 2025; $200M+ ARR (doubled 3 consecutive years); $6B valuation (merged Athelas); 130+ health systems; HCA partnership; acquired Augmedix $139M/Memora; healthcare RCM leader

AI VisibilityBeta
Overall Score
D34
Category Rank
#1 of 1
AI Consensus
58%
Trend
up
Per Platform
ChatGPT
45
Perplexity
45
Gemini
39

About

Commure is a healthcare infrastructure company founded to modernize the operational and clinical technology layer of health systems, which have historically relied on fragmented, decades-old software systems for workflows ranging from patient communication to revenue cycle management. The company was co-founded by Tanay Tandon and emerged from General Catalyst's health system subsidiary model, which provides capital and technology directly to large hospital networks. Commure merged with Athelas — an AI-powered revenue cycle management company — in 2023, combining Athelas's proven RCM automation with Commure's broader health system workflow platform to create a more comprehensive enterprise offering.\n\nCommure's platform addresses operational challenges across the health system enterprise including clinical documentation, ambient AI scribing through its Commure Scribe product, revenue cycle automation, patient engagement, and care team communication. The acquisition of Augmedix in 2024 added a leading ambient clinical intelligence capability, enabling physicians to automatically generate clinical notes from patient encounters using AI. Commure serves 130+ health systems and counts HCA Healthcare — one of the largest for-profit hospital networks in the US — as a strategic partner, providing both market validation and scale distribution for its products.\n\nCommure has achieved $200 million+ in annual recurring revenue, doubling for three consecutive years — a growth trajectory that has pushed its valuation to approximately $6 billion. The company's model of embedding deeply within health system operations, rather than selling point solutions that compete at the application layer, creates high switching costs and durable revenue streams. As health systems face intensifying margin pressure and clinician burnout driven by administrative overhead, Commure's AI-driven automation of clinical and operational workflows addresses two of the most urgent priorities simultaneously.

Full profile
CoverMyMeds logo

CoverMyMeds

LeaderHealthcare Revenue Cycle & Health IT

Prior Authorization & Medication Access

Largest prior authorization network in the US connecting 75K+ pharmacies, 750K+ providers, and all payers. Columbus OH; acquired by McKesson; available free to providers and pharmacies; processes millions of PA requests annually for specialty and retail prescriptions at no provider cost.

AI VisibilityBeta
Overall Score
A90
Category Rank
#1 of 1
AI Consensus
84%
Trend
up
Per Platform
ChatGPT
98
Perplexity
97
Gemini
92

About

CoverMyMeds is the largest prior authorization platform in the United States, operating a network that connects more than 750,000 providers, 75,000 pharmacies, and virtually all payers to streamline the authorization process for prescription medications. Founded in 2008 in Columbus, Ohio, and acquired by McKesson Corporation in 2017, CoverMyMeds processes millions of prior authorization requests annually and has become foundational infrastructure for the US pharmacy and specialty medication market. The platform is available at no cost to providers and pharmacies and is funded through health plan and PBM partnerships.\n\nCoverMyMeds' network effect is central to its value: because the platform is used by the vast majority of pharmacies and a very large share of prescribing providers, payers can reach their entire provider and pharmacy network through a single connection. The platform supports real-time benefit checks that show the formulary status and prior authorization requirements for a drug at the point of prescribing, enabling providers to make more informed prescribing decisions before a patient reaches the pharmacy counter. Automated electronic prior authorization (ePA) workflows reduce approval times from days to hours for eligible drug-payer combinations.\n\nAs part of McKesson, CoverMyMeds has expanded its capabilities to include specialty medication access solutions, patient assistance program enrollment, and medication adherence tools. The company's RxCrossroads subsidiary provides hub services for specialty pharmaceutical manufacturers, creating a comprehensive access ecosystem that spans from initial authorization through patient support and adherence management.

Full profile

AI Visibility Head-to-Head

34
Overall Score
90
#1
Category Rank
#1
58
AI Consensus
84
up
Trend
up
45
ChatGPT
98
45
Perplexity
97
39
Gemini
92
38
Claude
94
28
Grok
93

Key Details

Category
Healthcare Infrastructure
Prior Authorization & Medication Access
Tier
Emerging
Leader
Entity Type
brand
product

Capabilities & Ecosystem

Capabilities

Only Commure
Healthcare Infrastructure
Only CoverMyMeds
Prior Authorization & Medication Access
CoverMyMeds is classified as product (part of McKesson).

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.